Endocannabinoids and liver disease - Review

Liver International

Volumn 25, Issue 5, 2005, Pages 921-926

  Gabbay, Ezra ^a   Avraham, Yosefa ^a   Ilan, Yaron ^a   Israeli, Eran ^a   Berry, Elliot M ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

2 arachidonyl glycerol (2 AG); Cannabinoid receptors; CB1 receptor antagonist (SR141716A); Central nervous system (CNS); Neuromodulators

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; DRONABINOL; ENDOCANNABINOID; ENDOTOXIN; HU 320; ILLICIT DRUG; IMMUNOMODULATING AGENT; LIPOPOLYSACCHARIDE; NABILONE; NEW DRUG; PRS 211092; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANXIETY; APOPTOSIS; CHOLESTASIS; COGNITION; DRUG SAFETY; HEPATIC ENCEPHALOPATHY; HEPATITIS; HUMAN; HYPOTENSION; LIVER CELL; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TOXICITY; MOTOR COORDINATION; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NONHUMAN; PANIC; PATHOPHYSIOLOGY; PRURITUS; PSYCHOSIS; REVIEW; SHOCK; SIDE EFFECT;

ANIMALS; ARACHIDONIC ACIDS; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; LIVER DISEASES; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 26044432470     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01180.x     Document Type: Review

References (69)

1. Mechoulam R. The pharmacohistory of cannabis sativa. In: Mechoulam R., ed. Cannabinoids as Therapeutic Agents. Boca Raton: CRC Press, 1986; 1-18.
2. Indian Hemp Drugs Commission. Marijuana: Report of The Indian Hemp Drugs Commission, 1893-1894. Maryland: Silver Spring, 1969.
3. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of Hashish. J Am Chem Soc 1964; 86: 1646.
4. Devane WA, Dysarz FA III, Johnson M R, Melvine L S, Howlett A C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 35: 605-13.
5. Goutopoulos A, Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol Therapeut 2002; 95: 103-17.
6. Matsuda L A, Lolait S J, Brownstein M J. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
7. Liu J, Gao B, Mirshashi F, Sanyal A J, Khanolkar A D, Makriyyanis A, et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000; 346: 835-40.
8. Munro S, Thomas K, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
9. Devane W A, Hanus L, Breuer A, Pertwee R G, Stevenson L A, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
10. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski N E, Schatz A R, et al. Identification of an endogenous 2-monoglyceride, present in canine gut that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50(1): 83-90.
11. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in the brain. Biochem Biophys Res Commun 1995; 215: 89-97.
12. Hanus L, Abu Latfi S, Fride E, Breuer A, Vogel Z, Shalev D E, et al. 2-Arachidonoyl glycerol ether, endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98: 3662-5.
13. Martin B R, Mechoulam R, Razdan R K. Discovery and characterization of endogenous cannabinoids. Life Sci 1999; 65: 573-95.
14. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, et al. SR141716A a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-4.
15. Rinaldi-Carmona M, Barth F, Millan J, Derocq J M, Casellas P, Congy C, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284(2): 644-50.
16. Berry E M, Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002; 95: 185-90.
17. Pertwee R G. Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors. In: Pertwee RG, ed. Cannabinoid Receptors. London, San Diego: Academic Press, 1995; 69-83.
18. Calignano A, LaRana G, Giuffida A, Piomeeli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-81.
19. Walker J M, Hohmann G, Martin W J, Strangman N M. The neurobiology of cannabinoid analgesia. Life Sci 1999; 65: 665-73.
20. Varvel S A, Hamm R J, Martin B R, Lichtman A H. Differential effects of THC on the spatial reference and working memory in mice. Psychopharmacology 2001; 157: 142-50.
21. Lichtman A H. SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur J Pharmacol 2000; 404: 175-9; Berry et al. - unpublished data.
22. Hao S, Avraham Y, Mechoulam R, Berry E M. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet restricted mice. Eur J Pharmacol 2000; 392: 147-56.
23. Levitt M. Cannabinoids as antiemetics in cancer chemotherapy. In: Mechoulam R., ed. Cannabinoids as Therapeutic Agents. Boca Raton: CRC Press, 1986; 71-83.
24. Giuffrida A, Parsons L H, Kerr T M, Rodriguez De Fonesca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999; 2: 358-63.
25. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 1998; 5: 534-51.
26. Nahas GG, Sutin KM, Harvey DJ, Agurell S., eds. Marijuana and Medicine. Totowa: Humana Press, 1999.
27. Baker D, Pryce G, Croxford J L, Brown P, Pertwee R G, Makriyannis A, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15: 300-2.
28. Pertwee R G. Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95: 165-74.
29. Hampson R E, Deadwyler S A. Role of cannabinoid receptors in memory storage. Neurobiol Dis 1998; 5: 474-82.
30. Miskin E M, Cabral G A. Delta-9-tetrahydrocannabinol decreases host resistance to herpes simplex virus to herpes virus type 2 vaginal infection in B6C3F1 mice. J Gen Virol 1985; 66: 2539-49.
31. Galiegue S, Mary S, Marchand J. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54-61.
32. Kaminski N E, Koh W S, Yang K H, Lee M, Kessler F K. Supression of the humoral immune response by endocannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G protein coupled mechanism. Biochem Pharmacol 1994; 48(10): 1899-908.
33. Gallily R, Breuer A, Mechoulam R. 2-Arachidonyl-glycerol, an endogenous cannabinoid, inhibits tumor necrosis factor alpha production in murine macrophages and in mice. Eur J Pharmacol 2000; 406: R5-7.
34. Malfait A M, Gallily R, Sumarinawalla P F, Malik A S, Andreakos E, Mechoulam R, et al. The psychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen induced arthritis. Proc Natl Acad Sci USA 2000; 97: 9561-6.
35. Jarai Z, Wagner J, Varga K, Lake K D, Compton D R, Martin B R, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 1999; 96: 14136-41.
36. Arryo V, Gines P, Jimenenz W, Rodes J. Renal dysfunction in cirrhosis. In: Bircher J, Benhamou JP, McIntyre N, Rizzeto M, Rodes J., eds. Oxford Textbook of Clinical Hepatology, 2nd edn. Oxford: Oxford Medical Publications, 1999; 733-61.
37. Chan C C, Hwang S J, Lee F Y, Wang S S, Chang F Y, Li C P, et al. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand J Gastroenterol 1997; 32(9): 942-6.
38. Martin P Y, Gines P, Schrier R W, Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 553-41.
39. Wright S D, Ramos R A, Tobias P S, Ulevitch R J, Mathison J C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-3.
40. Dentener M A, Bazi V, Von Asmuth E J, Ceska M, Buurman WA. Involvement of CD14 in lipopolysaccharide-induced tumor necrosis factor-alpha, IL-6 and IL-8 release by human monocytes and alveolar macrophages. J. Immunol 1993; 150: 2885-91.
41. Di Marzo V, De Petrocellis L, Sepe N, Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J. 1996; 316: 977.
42. Wagner J A, Varga K, Ellis E F, Rzigalinski B A, Martin B R, Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 1997; 390: 518-21.
43. Varga K, Wagner J A, Bridgen D T, Kunos G. Platelet and macrophage derived endognous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998; 12: 1035-44.
44. Batkai S, Jarai Z, Wagner J A, Goparaju S K, Varga K, Liu J, et al. Endocannabinoids acting at vascular 1CB receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-32.
45. Ros R, Claria J, To-Figueras J, Planaguma A, Cejudo-Martin P, Fernandez-Varo G, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat gastroenterology, 2002; 122: 85-93.
46. Mukhopadhyay S, Chapnick B M, Howlett A C. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol 2002 Jun; 282(6): H2046-54.
47. Wang Y, Liu Y, Ito Y, Hashiguchi T, Kitajima I, Yamakuchi M, et al. Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Anal Biochem 2001; 294(1): 73-82.
48. McKallip R J, Lombard C, Martin B R, Nagarkatti M, Nagarkatti P S. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther 2002; 302(2): 451-65.
49. Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 2000; 275(41): 31938-45.
50. Biswas K K, Sarker K P, Abeyama K, Kawahara K, Iino S, Otsubo Y, et al. Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis. Hepatology 2003; 38(5): 1167-77.
51. Yurdaydin C, Li Y, Ha J-H, Rothman R, Basile A S. Brain and plasma levels of opiod peptides are altered in rats with thioacetamide induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opiod receptor antagonists. J Pharmacol Exp Ther 1995; 273: 185-92.
52. Bergasa N V, Rothman R B, Mukerjee E, Vergalla J, Jones EA. Up-regulation of central mu-opioid receptors in a model of hepatic encephalopathy: a potential mechanism for increased sensitivity to morphine in liver failure. Life Sci 2002; 22: 1701-8.
53. Gammal S H, Basile A S, Geller D, Skolnick P, Jones E A. Reversal of the 64 behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands. Hepatology 1990; 11: 371-8.
54. Basile A S, Harrison P M, Hughes R D, Gu Z O, Pannel L, McKinney A, et al. Relationship between plasma benzodiazepine receptor ligands and the severity of hepatic encephalopathy. Hepatology 1994; 19: 112-21.
55. Jones E A, Basile A S. Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure? Metab Brain Dis 1998; 13: 351-60.
56. Van Der Rijt C C, Schalm S W, Meulstee J, Stijnen T. Flumazenil therapy for hepatic encephalopathy. A double blind crossover study. Gastroenterol Clin Biol 1995; 19: 572-80.
57. Barbaro G, Di Lorenzo G, Solini M, Marziali M, Bellomo G, Belloni G, et al. Flumazenil for hepatic coma in patients with liver cirrhosis: an Italian multicentre double-blind, placebo-controlled, crossover study. Eur J Emer Med 1998; 5: 213-8.
58. Als-Nielsen B, Kjaergard L L, Gluud C. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev 2001; 4: CD002798.
59. Welch S P, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 1999; 848: 183-90.
60. Gabbay E, Avraham Y, Yisraeli E, Okun A, Zolotrev O, Zilberman I, et al. The endocannabinoid system affects neurological and cognitive function in an animal model of fulminant hepatic failure. Hepatology 2004; 40(suppl. 1): 502A.
61. Lavon I, Sheinin T, Meilin S, Biton E, Weksler A, Efroni G, et al. A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation. Mol Pharmacol 2003; 64(6): 1334-44.
62. Borini P, Guimaraes R C, Borini S B. Possible hepatotoxicity of chronic marijuana usage. Sao Paulo Med J 2004 May 6; 122(3): 110-6.
63. Neff G W, O'Brien C B, Reddy K R, Bergasa N V, Regev A, Molina E, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002; 97(8): 2117-9.
64. Gingold A R, Bergasa N V. The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sci 2003; 73(21): 2741-7.
65. Williamson E M, Evans F J. Cannabinoids in clinical practice. Drugs 2000; 60(6): 1303-14.
66. Sumariwalla P F, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 2004; 50(3): 985-98.
67. Gardner E L, Vorel R. Cannabinoid transmission and reward related events. Neurobiol Dis 1998; 5: 501-33.
68. Cleland J G, Ghosh J, Freemantle N, Kaye G C, Nasir M, Clark A L, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004; 6(4): 501-8.
69. Black S C. Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 2004; 5: 389-94.